ALK and non-small cell lung carcinoma: On the basis of practice guidelines from the United States, Canada, and Europe, (National Comprehensive Cancer Network, European Society for Medical Oncology, and American Society of Clinical Oncology/Ontario Health [Cancer Care Ontario]),3,10,11 the standard of care (SoC) for patients with EGFR- and ALK-negative NSCLC generally includes platinum-based therapy or immune checkpoint inhibitors (ICIs).